Efficacy of Entecavir therapy in elderly patients with chronic hepatitis B infection.
نویسندگان
چکیده
hronic infection with hepatitis B virus (CHB) affects as many s 350–400 million people worldwide and 93 million people n China.1 Moreover, elderly patients with CHB are increasing. ence, the treatment of elderly patients with CHB is an imporant issue. However, to our knowledge, there is no report about he efficacy of Entecavir (ETV) treatment on elderly patients ≥60 years) with CHB. A retrospective cohort study was conducted between ebruary 2006 and March 2008; 40 consecutive Chinese atients aged ≥60 years were enrolled in this study at Zheniang No. 3 Hospital. We also selected 40 patients aged <60 ears with CHB on ETV therapy at same time, who were atched to the ≥60 age group with respect to sex, alanine minotransferase (ALT), HBV-DNA level, HBV genotype, and BeAg status and duration of therapy. The study protocol was pproved by the ethics committees of the hospital. All patients ere treated with Entecavir at a dose of 0.5 mg/day peroral. Table 1 shows the rates of normalization of ALT level and on-detection of HBV-DNA, among patients aged ≥60 years nd <60 years after six months and three years on ETV therpy. The rates of ALT normalization of and of non-detection of BV-DNA in the two groups were similar (p > 0.05 for the two omparisons). Thirteen aged ≥60 years and nine patients aged ess than 60 years underwent long-term liver biopsy (median ime: 23 months, range: 12–39 months). Histological improveent (over 2-point decrease in the Knodell necroinflammatory
منابع مشابه
Association between KIR Genes and Efficacy of Treatment of HBeAg-Positive Chronic Hepatitis B Patients with Entecavir
Background: Entecavir (ETV) is commonly used to treat chronic hepatitis B (CHB) in China. However, certain percentages of e-Antigen (HBeAg) positive CHB patients do not respond to ETV therapy. Objective: To investigate whether the killer immunoglobulin-like receptor (KIR) genes were associated with seroconversion in HBeAg positive CHB responder patients treated with ETV. Methods: Polymerase cha...
متن کاملTreatment of Chronic Hepatitis B with Tenofovir
Background:Tenofovir is among the first-line treatments for chronic hepatitis B (CHB) virus infection. We evaluated the efficacy of Tenofovir in the treatment of Iranian adult patients with CHB. Methods: In a retrospective study, we evaluated 154 HBsAg positive patients referred to Sadoughi hospital in Yazd-Iran for treatment ...
متن کاملEffectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine
Little is known about the optimal treatment following the initial failure of interferon therapy and the potential different efficacy with de novo therapy with entecavir (ETV) or telbivudine (LDT) and following the interferon therapy failure.ETV or LDT therapy following the interferon therapy failure was compared with that of de novo therapy with ETV or LDT in patients with chronic hepatitis B v...
متن کاملClinical utility of entecavir for chronic hepatitis B in Chinese patients
The People's Republic of China has one of the highest rates of hepatitis B virus (HBV) infection. This review summarizes recent data from studies of entecavir, one of the recommended first-line oral therapies for treating chronic hepatitis B, in Chinese HBV-infected patients. Long-term treatment with entecavir is efficacious and well tolerated, and studies comparing entecavir with other nucleos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
دوره 18 6 شماره
صفحات -
تاریخ انتشار 2014